The objective of this study was to evaluate the effects of data-source and adjudication on indication classification and on estimates of the effectiveness of screening colonoscopy on late-stage colorectal cancer diagnosis risk.
We varied the values of several parameters in the baseline model and examined the effects these changes had on estimates of the effectiveness of confinement of ill persons to their homes (Table 4).
We varied the values of these parameters and examined the effects of these changes on estimates of the effectiveness of school closings and confining ill persons to their homes.
Additional studies are also needed to evaluate the impact of indication misclassification on estimates of the effectiveness of colonoscopy for reducing risk of CRC death.
Based on modeled estimates of the effectiveness of screening, the observed incidence of colorectal cancer in AmrA was adjusted to reflect the higher incidence that would have occurred if a small percentage of the population had not been screened [ 80].
Assuming that RSV-related hospitalizations for bronchiolitis were, as reported in the literature [ 2], 70% of the total, and that Palivizumab does not have any effect on non-RSV-related cases of bronchiolitis, we can further reduce our estimates of the effectiveness of Palivizumab on bronchiolitis hospitalizations of 30%.
We modeled the effects of ART program patient-year costs ranging from $500 to $1200 900% to 216% of our base estimate) on the cost-effectiveness of a supplement conferring a 20% reduction in both survival and retention (Additional file 1: Table S1 and Additional file 2: Figure S1).
To estimate their impact on the effectiveness of diffusion, we run a multivariate regression using the following equation: y=alpha_{0} + alpha_{1} theta + alpha_{2} delta + alpha_{3}s+ W' alpha_{4} + epsilon (1).
For example, RCTs of treatment A vs. placebo and treatment B vs. placebo would provide indirect estimates on the comparative effectiveness of A vs. B through the common reference placebo.
Our probabilistic sensitivity analysis quantifies the simultaneous impact of uncertainty in 35 independent variables (15 probabilities of clinical outcomes, 12 quality of life utilities, and eight cost estimates) on the incremental effectiveness, incremental costs, and ICER of MoM HRA compared to THA.
